高级检索
当前位置: 首页 > 详情页

Plasma metabolites and risk of seven cancers: a two-sample Mendelian randomization study among European descendants

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Respiratory Health, Frontiers Science Center for Disease‑Related Molecular Network, West China Hospital, Sichuan University, Guoxue Alley 37, Chengdu, Sichuan, China. [2]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [3]Center for Public Health Genomics, Department of Public Health Sciences, UVA Comprehensive Cancer Center, School of Medicine, University of Virginia, 560 Ray C. Hunt Dr., Rm 4408, Charlottesville, VA, USA. [4]Department of Public Health Sciences, UVA Comprehensive Cancer Center, School of Medicine, University of Virginia, Charlottesville, VA, USA. [5]Innovation Laboratory for Precision Diagnostics, Precision Medicine Research Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
出处:

关键词: Plasma metabolites Cancer risk Mendelian randomization

摘要:
While circulating metabolites have been increasingly linked to cancer risk, the causality underlying these associations remains largely uninterrogated.We conducted a comprehensive 2-sample Mendelian randomization (MR) study to evaluate the potential causal relationship between 913 plasma metabolites and the risk of seven cancers among European-ancestry individuals. Data on variant-metabolite associations were obtained from a genome-wide association study (GWAS) of plasma metabolites among 14,296 subjects. Data on variant-cancer associations were gathered from large-scale GWAS consortia for breast (N = 266,081), colorectal (N = 185,616), lung (N = 85,716), ovarian (N = 63,347), prostate (N = 140,306), renal cell (N = 31,190), and testicular germ cell (N = 28,135) cancers. MR analyses were performed with the inverse variance-weighted (IVW) method as the primary strategy to identify significant associations at Bonferroni-corrected P < 0.05 for each cancer type separately. Significant associations were subjected to additional scrutiny via weighted median MR, Egger regression, MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO), and reverse MR analyses. Replication analyses were performed using an independent dataset from a plasma metabolite GWAS including 8,129 participants of European ancestry.We identified 94 significant associations, suggesting putative causal associations between 66 distinct plasma metabolites and the risk of seven cancers. Remarkably, 68.2% (45) of these metabolites were each associated with the risk of a specific cancer. Among the 66 metabolites, O-methylcatechol sulfate and 4-vinylphenol sulfate demonstrated the most pronounced positive and negative associations with cancer risk, respectively. Genetically proxied plasma levels of these two metabolites were significantly associated with the risk of lung cancer and renal cell cancer, with an odds ratio and 95% confidence interval of 2.81 (2.33-3.37) and 0.49 (0.40-0.61), respectively. None of these 94 associations was biased by weak instruments, horizontal pleiotropy, or reverse causation. Further, 64 of these 94 were eligible for replication analyses, and 54 (84.4%) showed P < 0.05 with association patterns consistent with those shown in primary analyses.Our study unveils plausible causal relationships between 66 plasma metabolites and cancer risk, expanding our understanding of the role of circulating metabolites in cancer genetics and etiology. These findings hold promise for enhancing cancer risk assessment and prevention strategies, meriting further exploration.© 2024. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
第一作者:
第一作者机构: [1]Institute of Respiratory Health, Frontiers Science Center for Disease‑Related Molecular Network, West China Hospital, Sichuan University, Guoxue Alley 37, Chengdu, Sichuan, China. [2]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
通讯作者:
通讯机构: [1]Institute of Respiratory Health, Frontiers Science Center for Disease‑Related Molecular Network, West China Hospital, Sichuan University, Guoxue Alley 37, Chengdu, Sichuan, China. [2]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:54684 今日访问量:1 总访问量:4646 更新日期:2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号